This indicates that PHO patients, especially those with a high prevalence of gastrointestinal diseases should undergo regular blood or endoscopic monitoring during COX-2 inhibitor treatment to prevent more severe adverse effects, such as intestinal ulcers or bleeding. The gene discussed is PTGS2; the disease is primary hypertrophic osteoarthropathy.